Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Single Arm Study, Safety and Efficacy Assessment of the CD19 CAR T Cell on Pediatric Patients with Relapsing or Refractory B Cell Acute Lymphoblastic Leukemia (r/r B-ALL)

NCT06635330 is registered in ClinicalTrials.gov with Kara Yakhteh Tajhiz Azma Company as lead sponsor.

NCT NCT06635330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06635330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Single Arm Study, Safety and Efficacy Assessment of the CD19 CAR T Cell on Pediatric Patients with Relapsing or Refractory B Cell Acute Lymphoblastic Leukemia (r/r B-ALL)
Lead sponsor
Kara Yakhteh Tajhiz Azma Company
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 20, 2024
Completion date
September 22, 2027
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapse/refractory b-cell acute lymphoblastic leukemia